Klas Gosta Wiman

Corporate Officer/Principal at Karolinska Institutet

Health Technology

Consumer Services

Profile

Klas Gosta Wiman is the founder of Aprea Therapeutics, Inc. (founded in 2002) and Aprea Therapeutics AB (founded in 2003).
He is currently working as a Professor in the Oncology & Pathology Department at Karolinska Institutet.

Klas Gosta Wiman active positions

Companies	Position	Start
Karolinska Institutet	Corporate Officer/Principal	15/05/2009

All active positions of Klas Gosta Wiman

Former positions of Klas Gosta Wiman

Companies	Position	End
APREA THERAPEUTICS, INC.	Founder	-
Aprea Therapeutics AB Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden.	Founder	-

See the detail of Klas Gosta Wiman's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Klas Gosta Wiman's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
APREA THERAPEUTICS, INC.	Health Technology

Private companies	1
Aprea Therapeutics AB Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden.	Health Technology